首页 > 最新文献

JAMA Health Forum最新文献

英文 中文
JAMA Health Forum. 美国医学会杂志健康论坛。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.0536
{"title":"JAMA Health Forum.","authors":"","doi":"10.1001/jamahealthforum.2024.0536","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2024.0536","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"5 11","pages":"e240536"},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medical Devices Applying for Outpatient Medicare Supplemental Payments. 申请门诊医疗保险补充付款的医疗设备。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.4016
Osman Moneer, James L Johnston, Vinay K Rathi, Joseph S Ross, Sanket S Dhruva
<p><strong>Importance: </strong>Medicare transitional pass-through payments (TPTPs) provide supplemental reimbursement that is intended to facilitate adoption of new devices in the outpatient setting. The US Centers for Medicare & Medicaid Services (CMS) have historically evaluated manufacturer applications for TPTPs based on newness, cost, and evidence of substantial clinical improvement, ie, the traditional pathway. In 2020, CMS introduced an alternative pathway to allow US Food and Drug Administration (FDA)-designated breakthrough devices to qualify for supplemental reimbursement without demonstrating substantial clinical improvement.</p><p><strong>Objective: </strong>To characterize CMS TPTP approval rates and the premarket evidence used by FDA to support authorization of new outpatient medical devices considered for CMS TPTP.</p><p><strong>Design and setting: </strong>This was a cross-sectional study of TPTP applications for new outpatient medical devices from 2017 to 2023. Using the Federal Register, CMS Outpatient Prospective Payment System final rules for fiscal years 2017 through 2023 were obtained, from which all manufacturer applications for TPTPs were identified. For each application, the CMS TPTP review pathway (traditional/alternative), CMS final decision (award/deny), and FDA authorization pathway were assessed.</p><p><strong>Main outcomes and measures: </strong>Characteristics of devices considered for CMS TPTPs and design, effectiveness end points, and patient demographic characteristics of premarket clinical studies used to support FDA authorization.</p><p><strong>Results: </strong>CMS approved 17 of 43 (40%) applications for TPTPs, including all 8 (100%) alternative pathway applications for breakthrough devices and 9 of 35 applications (26%) using the traditional pathway. Devices approved for TPTPs were more likely to have been assessed in premarket clinical studies than devices denied TPTPs (12/17 [71%] vs 2/26 [8%]). Among the 14 premarket studies of TPTP-approved devices, 8 (57%) used surrogate markers as primary effectiveness end points and 5 (42%) did not meet all primary end points. The median (IQR) percentage of female, Black, and Hispanic patients among the trials that reported demographic data was 26% (17%-36%), 6% (2%-17%), and 4% (3%-5%), respectively.</p><p><strong>Conclusions and relevance: </strong>The findings of this cross-sectional analysis indicated that CMS more commonly awarded supplemental outpatient payment through TPTPs for devices assessed in premarket clinical studies to support FDA authorization. However, these studies often lacked generalizability to Medicare beneficiaries, used surrogate markers of effectiveness, or did not meet all primary end points. As more breakthrough devices receive FDA authorization and effectively qualify for automatic supplemental payments, strengthening premarket clinical evidence requirements for CMS TPTP approvals would provide better information to guide clinical decisio
重要性:医疗保险过渡性直通付款(TPTPs)提供补充补偿,旨在促进新设备在门诊环境中的应用。美国联邦医疗保险和医疗补助服务中心(CMS)历来根据新产品、成本和实质性临床改善的证据来评估制造商的 TPTPs 申请,即传统途径。2020 年,CMS 引入了另一种途径,允许美国食品和药物管理局(FDA)指定的突破性器械在不证明实质性临床改善的情况下获得补充报销:目的:描述 CMS TPTP 批准率的特点,以及 FDA 用于支持 CMS TPTP 考虑的新门诊医疗器械授权的上市前证据:这是对2017年至2023年新门诊医疗器械TPTP申请的横断面研究。通过《联邦公报》,我们获得了 CMS 门诊病人预付费系统 2017 至 2023 财年的最终规则,并从中确定了所有制造商的 TPTPs 申请。对于每项申请,都对 CMS TPTP 审查途径(传统/替代)、CMS 最终决定(批准/拒绝)和 FDA 授权途径进行了评估:主要结果和衡量标准:CMS TPTPs 考虑的器械特征以及用于支持 FDA 授权的上市前临床研究的设计、有效性终点和患者人口特征:CMS批准了43项TPTPs申请中的17项(40%),包括所有8项(100%)突破性器械替代途径申请和35项传统途径申请中的9项(26%)。与被拒绝 TPTP 的器械相比,获准 TPTP 的器械更有可能在上市前接受临床研究评估(12/17 [71%] vs 2/26 [8%])。在 14 项 TPTP 批准器械的上市前研究中,8 项(57%)使用替代标记物作为主要有效性终点,5 项(42%)未达到所有主要终点。在报告了人口统计学数据的试验中,女性、黑人和西班牙裔患者所占比例的中位数(IQR)分别为 26% (17%-36%)、6% (2%-17%) 和 4% (3%-5%):这项横断面分析的结果表明,CMS 通常通过 TPTPs 为上市前临床研究评估的器械提供门诊补充付款,以支持 FDA 的授权。然而,这些研究往往缺乏对医疗保险受益人的普遍性,使用了替代的有效性指标,或未达到所有主要终点。随着越来越多的突破性器械获得 FDA 授权并有效符合自动补充付款的条件,加强对 CMS TPTP 批准的上市前临床证据要求将提供更好的信息来指导临床决策,并确保补充付款能够加强对医疗保险受益人的护理。
{"title":"Medical Devices Applying for Outpatient Medicare Supplemental Payments.","authors":"Osman Moneer, James L Johnston, Vinay K Rathi, Joseph S Ross, Sanket S Dhruva","doi":"10.1001/jamahealthforum.2024.4016","DOIUrl":"10.1001/jamahealthforum.2024.4016","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Medicare transitional pass-through payments (TPTPs) provide supplemental reimbursement that is intended to facilitate adoption of new devices in the outpatient setting. The US Centers for Medicare & Medicaid Services (CMS) have historically evaluated manufacturer applications for TPTPs based on newness, cost, and evidence of substantial clinical improvement, ie, the traditional pathway. In 2020, CMS introduced an alternative pathway to allow US Food and Drug Administration (FDA)-designated breakthrough devices to qualify for supplemental reimbursement without demonstrating substantial clinical improvement.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To characterize CMS TPTP approval rates and the premarket evidence used by FDA to support authorization of new outpatient medical devices considered for CMS TPTP.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design and setting: &lt;/strong&gt;This was a cross-sectional study of TPTP applications for new outpatient medical devices from 2017 to 2023. Using the Federal Register, CMS Outpatient Prospective Payment System final rules for fiscal years 2017 through 2023 were obtained, from which all manufacturer applications for TPTPs were identified. For each application, the CMS TPTP review pathway (traditional/alternative), CMS final decision (award/deny), and FDA authorization pathway were assessed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Characteristics of devices considered for CMS TPTPs and design, effectiveness end points, and patient demographic characteristics of premarket clinical studies used to support FDA authorization.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;CMS approved 17 of 43 (40%) applications for TPTPs, including all 8 (100%) alternative pathway applications for breakthrough devices and 9 of 35 applications (26%) using the traditional pathway. Devices approved for TPTPs were more likely to have been assessed in premarket clinical studies than devices denied TPTPs (12/17 [71%] vs 2/26 [8%]). Among the 14 premarket studies of TPTP-approved devices, 8 (57%) used surrogate markers as primary effectiveness end points and 5 (42%) did not meet all primary end points. The median (IQR) percentage of female, Black, and Hispanic patients among the trials that reported demographic data was 26% (17%-36%), 6% (2%-17%), and 4% (3%-5%), respectively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;The findings of this cross-sectional analysis indicated that CMS more commonly awarded supplemental outpatient payment through TPTPs for devices assessed in premarket clinical studies to support FDA authorization. However, these studies often lacked generalizability to Medicare beneficiaries, used surrogate markers of effectiveness, or did not meet all primary end points. As more breakthrough devices receive FDA authorization and effectively qualify for automatic supplemental payments, strengthening premarket clinical evidence requirements for CMS TPTP approvals would provide better information to guide clinical decisio","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"5 11","pages":"e244016"},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Errors in Conflict of Interest Disclosures. 利益冲突披露中的错误。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.4268
{"title":"Errors in Conflict of Interest Disclosures.","authors":"","doi":"10.1001/jamahealthforum.2024.4268","DOIUrl":"10.1001/jamahealthforum.2024.4268","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"5 11","pages":"e244268"},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heat Waves and Adverse Health Events Among Dually Eligible Individuals 65 Years and Older. 热浪与 65 岁及以上符合双重资格者的不良健康事件。
IF 11.3 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.3884
Hyunjee Kim, Eun-Hye Yoo, Angela Senders, Clint Sergi, Hiroko H Dodge, Sue Anne Bell, Kyle D Hart

Importance: Extensive research has found the detrimental health effects of heat waves. However, a critical gap exists in understanding their association with adverse health events among older dually eligible individuals, who may be particularly susceptible to heat waves.

Objective: To assess the association between heat waves and adverse health events among dually eligible individuals 65 years and older.

Design, setting, and participants: This retrospective time-series study assessed the association between heat waves in warm months from 2016 to 2019 and zip code tabulation area (ZCTA)-day level adverse health events. Dually eligible individuals 65 years and older who were continuously enrolled in either a Medicare fee-for-service plan or a Medicare Advantage plan with full Medicaid benefits from May to September in any given year were identified. All ZCTAs in the US with at least 1 dually eligible individual in each study year were included. Data were analyzed from September 2023 to August 2024.

Exposure: Heat waves, defined as 3 or more consecutive extreme heat days (ie, days with a maximum temperature of at least 90 °F [32.2 °C] and in the 97th percentile of daily maximum temperatures for each ZCTA during the study period).

Main outcomes and measures: Daily counts of heat-related emergency department visits and heat-related hospitalizations for each ZCTA.

Results: The study sample included 5 448 499 beneficiaries 65 years and older in 28 404 ZCTAs across 50 states and Washington, DC; the mean (SD) proportion of female beneficiaries and beneficiaries 85 years and older in each ZCTA was 66% (7%) and 20% (8%), respectively. The incidence rate for heat-related emergency department visits was 10% higher during heat wave days compared to non-heat wave days (incidence rate ratio [IRR], 1.10; 95% CI, 1.08-1.12), and the incidence rate of heat-related hospitalizations was 7% higher during heat wave days (IRR, 1.07; 95% CI, 1.04-1.09). There were similar patterns in other adverse health events, including a 4% higher incidence rate of death during heat wave days (IRR, 1.04; 95% CI, 1.01-1.07). The magnitude of these associations varied across some subgroups. For example, the association between heat waves and heat-related emergency department visits was statistically significant only for individuals in 3 of 9 US climate regions: the Northwest, Ohio Valley, and the West.

Conclusions and relevance: In this time-series study, heat waves were associated with increased adverse health events among dually eligible individuals 65 years and older. Without adaptation strategies to address the health-related impacts of heat, dually eligible individuals are increasingly likely to face adverse outcomes.

重要性:大量研究发现,热浪会对健康产生不利影响。然而,在了解热浪与符合双重资格的老年人的不良健康事件之间的关系方面还存在重大差距,因为他们可能特别容易受到热浪的影响:目的:评估热浪与 65 岁及以上符合双重资格者的不良健康事件之间的关联:这项回顾性时间序列研究评估了 2016 年至 2019 年温暖月份的热浪与邮政编码制表区(ZCTA)日水平不良健康事件之间的关联。研究对象为 65 岁及以上、在任何一年的 5 月至 9 月期间连续加入联邦医疗保险付费服务计划或联邦医疗保险优势计划并享受全额医疗补助福利的符合双重资格的个人。研究对象包括美国所有 ZCTA,这些 ZCTA 在每个研究年度至少有一名符合双重资格的人员。数据分析时间为 2023 年 9 月至 2024 年 8 月。暴露:热浪,定义为连续 3 天或 3 天以上的极端高温日(即在研究期间,最高气温至少达到 90 °F [32.2 °C],且在每个 ZCTA 的日最高气温第 97 百分位数中):主要结果和测量指标:每个 ZCTA 中与高温有关的急诊就诊人数和与高温有关的住院人数的日计数:研究样本包括 50 个州和华盛顿特区 28 404 个 ZCTA 中 5 448 499 名 65 岁及以上的受益人;每个 ZCTA 中女性受益人和 85 岁及以上受益人的平均(标清)比例分别为 66% (7%) 和 20% (8%)。与非热浪日相比,热浪日与热有关的急诊就诊率高 10%(发病率比 [IRR], 1.10; 95% CI, 1.08-1.12),热浪日与热有关的住院就诊率高 7%(发病率比 [IRR], 1.07; 95% CI, 1.04-1.09)。其他不良健康事件也有类似的模式,包括热浪天的死亡发生率高出 4%(IRR,1.04;95% CI,1.01-1.07)。这些关联的程度在一些亚组中有所不同。例如,在美国的 9 个气候区中,只有 3 个气候区(西北部、俄亥俄河谷和西部)的人在热浪和与热有关的急诊就诊之间存在统计学意义上的关联:在这项时间序列研究中,热浪与 65 岁及以上符合双重资格的人群中不良健康事件的增加有关。如果不采取适应策略来应对热浪对健康的影响,符合双重资格的人越来越有可能面临不良后果。
{"title":"Heat Waves and Adverse Health Events Among Dually Eligible Individuals 65 Years and Older.","authors":"Hyunjee Kim, Eun-Hye Yoo, Angela Senders, Clint Sergi, Hiroko H Dodge, Sue Anne Bell, Kyle D Hart","doi":"10.1001/jamahealthforum.2024.3884","DOIUrl":"10.1001/jamahealthforum.2024.3884","url":null,"abstract":"<p><strong>Importance: </strong>Extensive research has found the detrimental health effects of heat waves. However, a critical gap exists in understanding their association with adverse health events among older dually eligible individuals, who may be particularly susceptible to heat waves.</p><p><strong>Objective: </strong>To assess the association between heat waves and adverse health events among dually eligible individuals 65 years and older.</p><p><strong>Design, setting, and participants: </strong>This retrospective time-series study assessed the association between heat waves in warm months from 2016 to 2019 and zip code tabulation area (ZCTA)-day level adverse health events. Dually eligible individuals 65 years and older who were continuously enrolled in either a Medicare fee-for-service plan or a Medicare Advantage plan with full Medicaid benefits from May to September in any given year were identified. All ZCTAs in the US with at least 1 dually eligible individual in each study year were included. Data were analyzed from September 2023 to August 2024.</p><p><strong>Exposure: </strong>Heat waves, defined as 3 or more consecutive extreme heat days (ie, days with a maximum temperature of at least 90 °F [32.2 °C] and in the 97th percentile of daily maximum temperatures for each ZCTA during the study period).</p><p><strong>Main outcomes and measures: </strong>Daily counts of heat-related emergency department visits and heat-related hospitalizations for each ZCTA.</p><p><strong>Results: </strong>The study sample included 5 448 499 beneficiaries 65 years and older in 28 404 ZCTAs across 50 states and Washington, DC; the mean (SD) proportion of female beneficiaries and beneficiaries 85 years and older in each ZCTA was 66% (7%) and 20% (8%), respectively. The incidence rate for heat-related emergency department visits was 10% higher during heat wave days compared to non-heat wave days (incidence rate ratio [IRR], 1.10; 95% CI, 1.08-1.12), and the incidence rate of heat-related hospitalizations was 7% higher during heat wave days (IRR, 1.07; 95% CI, 1.04-1.09). There were similar patterns in other adverse health events, including a 4% higher incidence rate of death during heat wave days (IRR, 1.04; 95% CI, 1.01-1.07). The magnitude of these associations varied across some subgroups. For example, the association between heat waves and heat-related emergency department visits was statistically significant only for individuals in 3 of 9 US climate regions: the Northwest, Ohio Valley, and the West.</p><p><strong>Conclusions and relevance: </strong>In this time-series study, heat waves were associated with increased adverse health events among dually eligible individuals 65 years and older. Without adaptation strategies to address the health-related impacts of heat, dually eligible individuals are increasingly likely to face adverse outcomes.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"5 11","pages":"e243884"},"PeriodicalIF":11.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAMA Health Forum Editorial Fellows-Call for Applicants. 美国医学会杂志》健康论坛编辑研究员--征集申请人。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.4573
Sandro Galea
{"title":"JAMA Health Forum Editorial Fellows-Call for Applicants.","authors":"Sandro Galea","doi":"10.1001/jamahealthforum.2024.4573","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2024.4573","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"5 11","pages":"e244573"},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Repeal of Subminimum Wages and Social Determinants of Health Among People With Disabilities. 废除最低工资与残疾人健康的社会决定因素。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.4034
Mihir Kakara, Elizabeth F Bair, Atheendar S Venkataramani

Importance: People with disabilities experience pervasive health disparities driven by adverse social determinants of health, such as unemployment. Section 14(c) of the 1938 Fair Labor Standards Act has been a controversial policy that allows people with disabilities to be paid below the prevailing minimum wage, but its impact on employment remains unknown despite ongoing national debates about its repeal.

Objective: To estimate whether state-level repeal of Section 14(c) was associated with employment-related outcomes for people with cognitive disability.

Design, setting, and participants: This quasi-experimental, synthetic difference-in-differences study used individual-level data from the 2010-2019 American Community Surveys. Outcomes before and after subminimum wage law repeal in 2 states (New Hampshire and Maryland) that repealed Section 14(c) were compared with a synthetic group of control states that did not implement repeal. Individuals aged 18 to 45 years who reported having a cognitive disability were included. Data were analyzed from May 2023 to May 2024.

Exposure: Repeal of Section 14(c) in New Hampshire (2015) and Maryland (2016).

Main outcomes and measures: Primary outcomes were labor force participation and employment rates. Secondary outcomes were annual wages, annual hours worked, hourly wages, and proportion earning above state minimum wage among employed individuals.

Results: The sample included 450 838 individuals. Of these, 253 157 (55.7%) were male, and the mean (SD) age was 31.3 (8.4) years. In state-specific analyses, New Hampshire's labor force participation and employment had a statistically significant increase by 5.2 percentage points (β = 0.05; 95% CI, 0-0.10; P = .04) and 7 percentage points (β = 0.07; 95% CI, 0.01-0.13; P = .03), respectively, following Section 14(c) repeal. Labor force participation and employment both increased in Maryland, although estimates were not statistically significant. Pooling both states, Section 14(c) repeal was associated with a statistically significant 4.7-percentage point (β = 0.05; 95% CI, 0.01-0.08; P = .01) increase in labor force participation and a nonsignificant 4.3-percentage point (β = 0.04; 95% CI, 0-0.09; P = .07) increase in employment.

Conclusions and relevance: In this study, repeal of Section 14(c), a policy allowing subminimum wages for people with disabilities, led to increases in labor force participation, though with heterogeneity at the state level. These findings suggest the importance of state-level factors in shaping program effects, especially as national-level Section 14(c) repeal is being debated.

重要性:由于失业等不利于健康的社会决定因素,残疾人在健康方面普遍存在差异。1938 年的《公平劳动标准法案》第 14(c)条是一项有争议的政策,它允许残疾人的工资低于现行的最低工资标准,尽管全国范围内一直在讨论废除该条款的问题,但其对就业的影响仍不得而知:估计州一级废除第 14(c)条是否与认知障碍者的就业相关结果有关:这项准实验性合成差异研究使用了 2010-2019 年美国社区调查的个人层面数据。将两个废除了第14(c)条的州(新罕布什尔州和马里兰州)废除最低工资法前后的结果与未废除最低工资法的合成对照组进行了比较。研究对象包括年龄在 18 至 45 岁之间、报告有认知障碍的个人。数据分析时间为 2023 年 5 月至 2024 年 5 月:暴露:新罕布什尔州(2015 年)和马里兰州(2016 年)废除第 14(c)条:主要结果是劳动力参与率和就业率。次要结果是年工资、年工时、小时工资以及就业人员中收入高于州最低工资的比例:样本包括 450 838 人。其中,253 157 人(55.7%)为男性,平均年龄为 31.3(8.4)岁。在针对各州的分析中,新罕布什尔州的劳动力参与率和就业率在废除第 14(c)条后分别增加了 5.2 个百分点 (β = 0.05; 95% CI, 0-0.10; P = .04) 和 7 个百分点 (β = 0.07; 95% CI, 0.01-0.13; P = .03),具有显著的统计学意义。马里兰州的劳动力参与率和就业率均有所上升,但估计值在统计上并不显著。将这两个州汇总在一起,第 14(c)条的废除与劳动力参与率增加 4.7 个百分点(β = 0.05;95% CI,0.01-0.08;P = .01)和就业率增加 4.3 个百分点(β = 0.04;95% CI,0-0.09;P = .07)具有统计学意义:在本研究中,废除第 14(c)条(允许残疾人领取最低以下工资的政策)导致了劳动力参与率的提高,尽管在州一级存在异质性。这些研究结果表明,州一级的因素对计划效果的形成非常重要,尤其是在全国范围内废除第 14(c) 条的讨论正在进行的时候。
{"title":"Repeal of Subminimum Wages and Social Determinants of Health Among People With Disabilities.","authors":"Mihir Kakara, Elizabeth F Bair, Atheendar S Venkataramani","doi":"10.1001/jamahealthforum.2024.4034","DOIUrl":"10.1001/jamahealthforum.2024.4034","url":null,"abstract":"<p><strong>Importance: </strong>People with disabilities experience pervasive health disparities driven by adverse social determinants of health, such as unemployment. Section 14(c) of the 1938 Fair Labor Standards Act has been a controversial policy that allows people with disabilities to be paid below the prevailing minimum wage, but its impact on employment remains unknown despite ongoing national debates about its repeal.</p><p><strong>Objective: </strong>To estimate whether state-level repeal of Section 14(c) was associated with employment-related outcomes for people with cognitive disability.</p><p><strong>Design, setting, and participants: </strong>This quasi-experimental, synthetic difference-in-differences study used individual-level data from the 2010-2019 American Community Surveys. Outcomes before and after subminimum wage law repeal in 2 states (New Hampshire and Maryland) that repealed Section 14(c) were compared with a synthetic group of control states that did not implement repeal. Individuals aged 18 to 45 years who reported having a cognitive disability were included. Data were analyzed from May 2023 to May 2024.</p><p><strong>Exposure: </strong>Repeal of Section 14(c) in New Hampshire (2015) and Maryland (2016).</p><p><strong>Main outcomes and measures: </strong>Primary outcomes were labor force participation and employment rates. Secondary outcomes were annual wages, annual hours worked, hourly wages, and proportion earning above state minimum wage among employed individuals.</p><p><strong>Results: </strong>The sample included 450 838 individuals. Of these, 253 157 (55.7%) were male, and the mean (SD) age was 31.3 (8.4) years. In state-specific analyses, New Hampshire's labor force participation and employment had a statistically significant increase by 5.2 percentage points (β = 0.05; 95% CI, 0-0.10; P = .04) and 7 percentage points (β = 0.07; 95% CI, 0.01-0.13; P = .03), respectively, following Section 14(c) repeal. Labor force participation and employment both increased in Maryland, although estimates were not statistically significant. Pooling both states, Section 14(c) repeal was associated with a statistically significant 4.7-percentage point (β = 0.05; 95% CI, 0.01-0.08; P = .01) increase in labor force participation and a nonsignificant 4.3-percentage point (β = 0.04; 95% CI, 0-0.09; P = .07) increase in employment.</p><p><strong>Conclusions and relevance: </strong>In this study, repeal of Section 14(c), a policy allowing subminimum wages for people with disabilities, led to increases in labor force participation, though with heterogeneity at the state level. These findings suggest the importance of state-level factors in shaping program effects, especially as national-level Section 14(c) repeal is being debated.</p>","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"5 11","pages":"e244034"},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Title Updated. 标题已更新。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.4847
{"title":"Title Updated.","authors":"","doi":"10.1001/jamahealthforum.2024.4847","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2024.4847","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"5 11","pages":"e244847"},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142734580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgeon Workforce in Underserved Communities. 服务不足社区的外科医生队伍。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.3531
Crystal D Taylor, Sara L Schaefer, Adrian Diaz, Nicholas Kunnath, John W Scott, Andrew M Ibrahim
{"title":"Surgeon Workforce in Underserved Communities.","authors":"Crystal D Taylor, Sara L Schaefer, Adrian Diaz, Nicholas Kunnath, John W Scott, Andrew M Ibrahim","doi":"10.1001/jamahealthforum.2024.3531","DOIUrl":"10.1001/jamahealthforum.2024.3531","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"5 11","pages":"e243531"},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cannabis Use During Early Pregnancy Following Recreational Cannabis Legalization. 娱乐性大麻合法化后怀孕早期的大麻使用情况。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.3656
Kelly C Young-Wolff, Natalie E Slama, Lyndsay A Avalos, Alisa A Padon, Lynn D Silver, Sara R Adams, Monique B Does, Deborah Ansley, Carley Castellanos, Cynthia I Campbell, Stacey E Alexeeff
<p><strong>Importance: </strong>It is unknown whether state recreational cannabis legalization (RCL) is related to increased rates of prenatal cannabis use or whether RCL-related changes vary with cannabis screening methods or the local policy environment.</p><p><strong>Objective: </strong>To test whether RCL in California was associated with changes in prenatal cannabis use rates, whether changes were evident in both self-report and urine toxicology testing, and whether rates varied by local policies banning vs allowing adult-use retailers post-RCL.</p><p><strong>Design, setting, and participants: </strong>This population-based time-series study used data from pregnancies in Kaiser Permanente Northern California universally screened for cannabis use during early pregnancy by self-report and toxicology testing from January 1, 2012, to December 31, 2019. Analyses were conducted from September 2022 to August 2024.</p><p><strong>Exposures: </strong>California state RCL passage (November 9, 2016) and implementation of legal sales (January 1, 2018) were examined with a 1-month lag. Local policies allowing vs banning medical retailers pre-RCL and adult-use retailers post-RCL were also examined.</p><p><strong>Main outcomes and measures: </strong>Any prenatal cannabis use was based on screening at entrance to prenatal care (typically at 8-10 weeks' gestation) and defined as (1) a positive urine toxicology test result or self-report, (2) a positive urine toxicology test result, or (3) self-report. Interrupted time series models were fit using Poisson regression, adjusting for age, race and ethnicity, and neighborhood deprivation index.</p><p><strong>Results: </strong>The sample of 300 993 pregnancies (236 327 unique individuals) comprised 25.9% Asian individuals, 6.4% Black individuals, 26.0% Hispanic individuals, 37.7% White individuals, and 4.1% individuals of other, multiple, or unknown race, with a mean (SD) age of 30.3 (5.4) years. Before RCL implementation, rates of prenatal cannabis use rose steadily from 4.5% in January 2012 to 7.1% in January 2018. There was no change in use rates at the time of RCL passage (level change rate ratio [RR], 1.03; 95% CI, 0.96-1.11) and a statistically significant increase in rates in the first month after RCL implementation, increasing to 8.6% in February 2018 (level change RR, 1.10; 95% CI, 1.04-1.16). Results were similar when defining prenatal cannabis use by (1) a toxicology test or (2) self-report. In local policy analyses, the post-RCL implementation increase in use was only found among those in jurisdictions allowing adult-use cannabis retailers (allowed RR, 1.21; 95% CI, 1.10-1.33; banned RR, 1.01; 95% CI, 0.93-1.10).</p><p><strong>Conclusions and relevance: </strong>In this time-series study, RCL implementation in California was associated with an increase in rates of cannabis use during early pregnancy, defined by both self-report and toxicology testing, driven by individuals living in jurisdictions that a
重要性:目前尚不清楚各州娱乐大麻合法化(RCL)是否与产前大麻使用率增加有关,也不清楚与 RCL 有关的变化是否因大麻筛查方法或当地政策环境而异:目的: 检验加利福尼亚州的 RCL 是否与产前大麻使用率的变化有关,自我报告和尿液毒理学检测中的变化是否明显,以及 RCL 后禁止与允许成人使用零售商的地方政策是否会导致产前大麻使用率的变化:这项基于人群的时间序列研究使用了北加州凯泽医疗机构(Kaiser Permanente Northern California)从 2012 年 1 月 1 日至 2019 年 12 月 31 日通过自我报告和毒理学检测对怀孕早期使用大麻的孕妇进行普遍筛查的数据。分析时间为 2022 年 9 月至 2024 年 8 月:加利福尼亚州 RCL 的通过(2016 年 11 月 9 日)和合法销售的实施(2018 年 1 月 1 日)滞后 1 个月进行研究。此外,还对 RCL 之前允许与禁止医疗零售商以及 RCL 之后允许与禁止成人使用零售商的地方政策进行了研究:任何产前大麻使用情况均基于产前护理入门时(通常在妊娠 8-10 周时)的筛查,并定义为(1)尿液毒理学检测结果呈阳性或自我报告,(2)尿液毒理学检测结果呈阳性,或(3)自我报告。采用泊松回归法拟合间断时间序列模型,并对年龄、种族和民族以及邻里贫困指数进行调整:样本中有 300 993 名孕妇(236 327 人),其中亚裔占 25.9%,黑人占 6.4%,西班牙裔占 26.0%,白人占 37.7%,其他、多重或未知种族占 4.1%,平均(标清)年龄为 30.3 (5.4)岁。在实施 RCL 之前,产前大麻使用率从 2012 年 1 月的 4.5% 稳步上升至 2018 年 1 月的 7.1%。在 RCL 通过时,使用率没有变化(水平变化率比 [RR],1.03;95% CI,0.96-1.11),而在 RCL 实施后的第一个月,使用率出现了统计意义上的显著增长,在 2018 年 2 月增至 8.6%(水平变化率比,1.10;95% CI,1.04-1.16)。当通过(1)毒理学测试或(2)自我报告来定义产前大麻使用时,结果相似。在地方政策分析中,只有在允许成人使用大麻零售商的辖区内,才会发现 RCL 实施后使用量的增加(允许 RR,1.21;95% CI,1.10-1.33;禁止 RR,1.01;95% CI,0.93-1.10):在这项时间序列研究中,加利福尼亚州 RCL 的实施与妊娠早期大麻使用率的增加有关,妊娠早期大麻使用率由自我报告和毒理学测试确定,由生活在允许成人使用零售商辖区的个人驱动。
{"title":"Cannabis Use During Early Pregnancy Following Recreational Cannabis Legalization.","authors":"Kelly C Young-Wolff, Natalie E Slama, Lyndsay A Avalos, Alisa A Padon, Lynn D Silver, Sara R Adams, Monique B Does, Deborah Ansley, Carley Castellanos, Cynthia I Campbell, Stacey E Alexeeff","doi":"10.1001/jamahealthforum.2024.3656","DOIUrl":"10.1001/jamahealthforum.2024.3656","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;It is unknown whether state recreational cannabis legalization (RCL) is related to increased rates of prenatal cannabis use or whether RCL-related changes vary with cannabis screening methods or the local policy environment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To test whether RCL in California was associated with changes in prenatal cannabis use rates, whether changes were evident in both self-report and urine toxicology testing, and whether rates varied by local policies banning vs allowing adult-use retailers post-RCL.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This population-based time-series study used data from pregnancies in Kaiser Permanente Northern California universally screened for cannabis use during early pregnancy by self-report and toxicology testing from January 1, 2012, to December 31, 2019. Analyses were conducted from September 2022 to August 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposures: &lt;/strong&gt;California state RCL passage (November 9, 2016) and implementation of legal sales (January 1, 2018) were examined with a 1-month lag. Local policies allowing vs banning medical retailers pre-RCL and adult-use retailers post-RCL were also examined.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Any prenatal cannabis use was based on screening at entrance to prenatal care (typically at 8-10 weeks' gestation) and defined as (1) a positive urine toxicology test result or self-report, (2) a positive urine toxicology test result, or (3) self-report. Interrupted time series models were fit using Poisson regression, adjusting for age, race and ethnicity, and neighborhood deprivation index.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The sample of 300 993 pregnancies (236 327 unique individuals) comprised 25.9% Asian individuals, 6.4% Black individuals, 26.0% Hispanic individuals, 37.7% White individuals, and 4.1% individuals of other, multiple, or unknown race, with a mean (SD) age of 30.3 (5.4) years. Before RCL implementation, rates of prenatal cannabis use rose steadily from 4.5% in January 2012 to 7.1% in January 2018. There was no change in use rates at the time of RCL passage (level change rate ratio [RR], 1.03; 95% CI, 0.96-1.11) and a statistically significant increase in rates in the first month after RCL implementation, increasing to 8.6% in February 2018 (level change RR, 1.10; 95% CI, 1.04-1.16). Results were similar when defining prenatal cannabis use by (1) a toxicology test or (2) self-report. In local policy analyses, the post-RCL implementation increase in use was only found among those in jurisdictions allowing adult-use cannabis retailers (allowed RR, 1.21; 95% CI, 1.10-1.33; banned RR, 1.01; 95% CI, 0.93-1.10).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In this time-series study, RCL implementation in California was associated with an increase in rates of cannabis use during early pregnancy, defined by both self-report and toxicology testing, driven by individuals living in jurisdictions that a","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"5 11","pages":"e243656"},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considerations for Academic Medical Centers Moving AHEAD. 学术医疗中心前进道路上的注意事项。
IF 9.5 Q1 HEALTH CARE SCIENCES & SERVICES Pub Date : 2024-11-01 DOI: 10.1001/jamahealthforum.2024.3781
Anjali Bhatla, Scott A Berkowitz
{"title":"Considerations for Academic Medical Centers Moving AHEAD.","authors":"Anjali Bhatla, Scott A Berkowitz","doi":"10.1001/jamahealthforum.2024.3781","DOIUrl":"https://doi.org/10.1001/jamahealthforum.2024.3781","url":null,"abstract":"","PeriodicalId":53180,"journal":{"name":"JAMA Health Forum","volume":"5 11","pages":"e243781"},"PeriodicalIF":9.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA Health Forum
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1